NCT00314873View on ClinicalTrials.gov

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Thymic Carcinoma
Interventions
DRUG

Gleevec (imatinib)

Imatinib 600mg po qd X 21 days.

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
lead

Indiana University School of Medicine

OTHER

NCT00314873 - Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma | Biotech Hunter | Biotech Hunter